JCB, Volume 16, Number 4, 2010 Editorial Vol.16 No. 4 (2010) For success in biotechnology, look beyond biotechnology Yali Friedman The fates of biotechnology companies can be fairly described as volatile. Clinical trial progress, patent grants and invalidations, and funding announcements can yield grea Commentary Vol.16 No. 4 (2010) Federal bureaucrats slip on oil spill Henry I Miller   Article Vol.16 No. 4 (2010) R&D spending and sources of funding of private US biopharmaceutical firms seeking to go public David R Williams This study analyzes the relationship between the amount of research and development (R&D) spending in private US biopharmaceutical firms before they go public and w Article Vol.16 No. 4 (2010) Algae and Biodiesel: Patenting energized as green goes commercial Matthew R Preiss In the twenty-first century, predominant dependence on fossil fuels as energy resources will not be sustainable. Developing and commercializing green energy innovations Article Vol.16 No. 4 (2010) Biotechnology industry-physician interaction and OIG guidelines: Evidence from the stock market Thani Jambulingam Our article investigates the stock market reaction of the issuance of guidelines by the Office of Inspector General (OIG) to prod biotechnology manufacturers to strengt Article Vol.16 No. 4 (2010) Exploratory assessment of the current EU regulatory framework for development of advanced therapies Pawanbir Singh The Advanced Therapy Medicinal Products (ATMP) Regulation provides a necessary regulatory framework for the commercialisation and use of regenerative medicine-based the Article Vol.16 No. 4 (2010) Patenting of microorganisms: Systems and concerns Ramkumar Balachandra Nair The Government of India permitted patenting of microorganisms in India under the Patents (Second Amendment) Bill, 2002, which was passed by the Parliament on 14 May 200 Legal and Regulatory Updates Vol.16 No. 4 (2010) Legal and Regulatory Update Gerry Kamstra   Legal and Regulatory Updates Vol.16 No. 4 (2010) The aftermath of Bilski Thomas C Meyers   Legal and Regulatory Updates Vol.16 No. 4 (2010) Commentary regarding decision in Bilski from a biotech perspective Thomas J Kowalski   Book Review Vol.16 No. 4 (2010) Book Review: Biodesign: The process of innovating medical technologies Randall Tagg Biodesign: The process of innovating medical technologiesStefanos Zenios, Josh Makower, Paul Yock, Todd J. Brinton, Uday N. Kumar, Lyn Denend, Thomas M. Krummel and Christine Kurih
